Safety and efficacy of immune checkpoint inhibitors in patients with pre-treatment reduced left ventricular function
Rattachement africain : il, nl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
AIMS: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment outcomes. However, the response varies across different populations, and their use may lead to life-threatening cardiovascular (CV) events. While pre-treatment reduced left ventricular ejection fraction (LVEF) is considered a marker for high-risk cardiotoxicity and a contraindication for anthracycline and HER2-targeted therapies, there is limited evidence on the safety and efficacy of ICIs therapy in patients presenting with pre-treatment reduced LVEF. The study aims to evaluate the safety and efficacy of ICIs therapy in patients with pre-treatment reduced LVEF. METHODS: Retrospective single center cohort of patients treated with ICIs therapy, who performed pre-treatment LVEF assessment. The primary endpoint was to evaluate the safety of ICIs among this population, assessed by CV events (composite of myocarditis, acute coronary syndrome, heart failure, and arrhythmias). The secondary endpoint was to evaluate the efficacy of ICIs, assessed by all-cause mortality and progression-free survival (PFS). RESULTS: The cohort included 307 patients, with 30 (10%) presenting with pre-treatment reduced LVEF, with a mean LVEF of 39 ± 7%. While a significantly higher incidence of CV events was observed in the reduced LVEF group (37% vs. 14%, p = 0.004), following a multivariate Cox regression analysis including baseline CV diseases and risk factors, pre-treatment reduced LVEF did not remain a significant independent predictor (p = 0.358). No significant differences were observed between the groups regarding all-cause mortality and PFS. CONCLUSIONS: Pre-treatment reduced LVEF was not identified as an independent marker for clinical outcomes in patients treated with ICIs therapy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Safety and efficacy of immune checkpoint inhibitors in patients with pre-treatment reduced left ventricular function
- Date Crossref
- 08/01/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Tel Aviv University pays non établi dans la noticeUniversité ou école supérieure
-
Tel Aviv Sourasky Medical Center Division of Cardiology pays non établi dans la noticeÉtablissement de santé
-
Radboud University Nijmegen pays non établi dans la noticeUniversité ou école supérieure
-
Radboud University Medical Center pays non établi dans la noticeOrganisme public
-
Weizmann Institute of Science pays non établi dans la noticeUniversité ou école supérieure
-
School of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Radboud University Medical Centre Department of Pediatrics Cardiology pays non établi dans la noticeUniversité ou école supérieure
Tel Aviv University, Division of Cardiology — Tel Aviv Sourasky Medical Center et Radboud University Nijmegen, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.